Supply of Trial Drug Sample Clauses

Supply of Trial Drug. Sponsor will supply the Investigational Product, if applicable, for use in the Trial at no cost to Institution or Investigator. Sponsor may also supply or arrange for the provision of any other Trial Drug to be used in the Trial at no cost to Institution or Investigator, either through provision of such Trial Drug by Sponsor or reimbursement to Institution by a third party payor. Institution and Investigator acknowledge and declare that supply by
Sample 1
AutoNDA by SimpleDocs
Supply of Trial Drug. Sponsor will supply the Investigational Product, if applicable, for use in the Trial at no cost to Institution or Investigator. Institution and Investigator acknowledge and declare that supply by the Trial Drug at no cost is not intended to provide, directly or indirectly, as a reward or compensation for Institution and Investigator, and not a condition of ordering, prescribing or recommending products or services and the Sponsor. 2.1 Dodávka Klinicky hodnoceného léčiva. Zadavatel dodá případný Hodnocený léčivý přípravek k použití v Klinickém hodnocení bezplatně Zdravotnickému zařízení nebo Zkoušejícímu. Zdravotnické zařízení a Zkoušející berou na vědomí a prohlašují, že bezplatné dodání Klinicky hodnoceného léčiva není zamýšleno jako přímé nebo nepřímé poskytnutí odměny nebo náhrady Zdravotnickému zařízení a Zkoušejícímu, ani jako podmínka pro objednání, předepisování nebo doporučování výrobků nebo služeb a Zadavatele.
Sample 1
Supply of Trial Drug. Sponsor will supply the Investigational Product, if applicable, for use in the Trial at no cost to Pharmacy of Institution always properly packed in containers stated for Trial Drug and labeled in according to § 19, par. 1, letter e), Regulation No. 226/2008 Coll. Shipment delivery will take place in business days and during normal business hours in the building of Institution´s Pharmacy. Sponsor may also supply or arrange for the provision of any other Trial Drug to be used in the Trial at no cost to Institution or Investigator, either through provision of such Trial Drug by Sponsor or reimbursement to Institution by a third party payor. Institution and Investigator acknowledge and declare that supply by the Trial Drug at no cost is not intended to provide, directly or indirectly, as a reward or
Sample 1
Supply of Trial Drug. Sponsor will supply the Investigational Product, if applicable, for use in the Trial at no cost to Institution. Sponsor may also supply or arrange for the provision of any other Trial Drug to be used in the Trial e.g. comparator, placebo at no cost to Institution, either through provision of such Trial Drug by Sponsor or reimbursement to Institution by a third party payor. Institution acknowledges and declares that supply by the Trial Drug at no cost is not intended to provide, directly or indirectly, as a reward or compensation for Institution, and not a condition of ordering, prescribing or recommending products or services and the Sponsor. 4.1 Dodávka Klinicky hodnoceného léčiva. Zadavatel dodá případný Hodnocený léčivý přípravek k použití v Klinickém hodnocení bezplatně Zdravotnickému zařízení. Zadavatel může rovněž Zdravotnickému zařízení bezplatně dodat nebo zajistit poskytnutí jiného Klinicky hodnoceného léčiva k použití při Klinickém hodnocení, např. srovnávacího léčiva, placeba a to buď přímo, nebo poskytnutím náhrady třetí osobě za jeho poskytnutí Zdravotnickému zařízení. Zdravotnické zařízení bere na vědomí a prohlašuje, že bezplatné dodání Klinicky hodnoceného léčiva není zamýšleno jako přímé nebo nepřímé poskytnutí odměny nebo náhrady Zdravotnickému zařízení, ani jako podmínka pro objednání, předepisování nebo doporučování výrobků nebo služeb a Zadavatele.
Sample 1
Supply of Trial Drug. Sponsor will supply the Investigational Product (dabigatran etexilate) for use in the Trial at no cost to Provider or Investigator. If needed by Protocol Sponsor will also supply or arrange for the provision of any other Trial Drug to be used in the Trial at no cost to Provider or Investigator, either through provision of such Trial Drug by Sponsor or reimbursement to Provider by a third party payor. Provider and Investigator acknowledge and declare that supply by the Trial Drug at no cost is not intended to provide, directly or indirectly, as a reward or compensation for Provider and Investigator, and not a condition of ordering, prescribing or recommending products or services and the Sponsor.
Sample 1
Supply of Trial Drug. Sponsor will supply the Investigational Product, if applicable, for use in the Trial at no cost to Institution or Investigator. Sponsor may also supply or arrange for the provision of any other Trial Drug to be used in the Trial at no cost to Institution or Investigator, either through provision of such Trial Drug by Sponsor or by providing a refund. Institution and Investigator acknowledge and declare that supply by the Trial Drug at no cost is not intended to provide, directly or indirectly, as a reward or compensation for Institution and Investigator, and not a condition of ordering, prescribing or recommending products or services and the Sponsor. 2.1 Dodávka Klinicky hodnoceného léčiva. Zadavatel dodá případný Hodnocený léčivý přípravek k použití v Klinickém hodnocení bezplatně Zdravotnickému zařízení nebo Zkoušejícímu. Zadavatel může rovněž Zdravotnickému zařízení nebo Zkoušejícímu bezplatně dodat nebo zajistit poskytnutí jiného Klinicky hodnoceného léčiva k použití při Klinickém hodnocení, a to xxx xxxxx, nebo poskytnutím náhrady Zdravotnickému zařízení. Zdravotnické zařízení a Zkoušející berou na vědomí a prohlašují, že bezplatné xxxxxx Klinicky hodnoceného léčiva není zamýšleno jako přímé nebo nepřímé poskytnutí odměny nebo náhrady Zdravotnickému zařízení a Zkoušejícímu, xxx xxxx podmínka pro objednání, předepisování nebo doporučování výrobků nebo služeb a Zadavatele.
Sample 1

Related to Supply of Trial Drug

  • Technical Standards Applicable to a Wind Generating Plant i. Low Voltage Ride-Through (LVRT) Capability A wind generating plant shall be able to remain online during voltage disturbances up to the time periods and associated voltage levels set forth in the standard below. The LVRT standard provides for a transition period standard and a post-transition period standard.

  • Background Screening VENDOR shall comply with all requirements of Sections 1012.32 and 1012.465, Florida Statutes, and all of its personnel who (1) are to be permitted access to school grounds when students are present, (2) will have direct contact with students, or (3) have access or control of school funds, will successfully complete the background screening required by the referenced statutes and meet the standards established by the statutes. This background screening will be conducted by SBBC in advance of VENDOR or its personnel providing any services under the conditions described in the previous sentence. VENDOR shall bear the cost of acquiring the background screening required by Section 1012.32, Florida Statutes, and any fee imposed by the Florida Department of Law Enforcement to maintain the fingerprints provided with respect to VENDOR and its personnel. The parties agree that the failure of VENDOR to perform any of the duties described in this section shall constitute a material breach of this Agreement entitling SBBC to terminate immediately with no further responsibilities or duties to perform under this Agreement. VENDOR agrees to indemnify and hold harmless SBBC, its officers and employees from any liability in the form of physical or mental injury, death or property damage resulting from VENDOR’s failure to comply with the requirements of this section or with Sections 1012.32 and 1012.465, Florida Statutes.

  • REGULATORY FILINGS AND CAISO TARIFF COMPLIANCE 3.1 Filing

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Territorial application This Agreement shall apply, on the one hand, to the territories in which the Treaty establishing the European Community is applied, and under the conditions laid down in that Treaty and, on the other hand, to the territory of the United States.

Time is Money Join Law Insider Premium to draft better contracts faster.